Compare Stocks: REVB, LPCN, TVRD, and BFRI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$1.35 +3.8%	$1.08	$0.55 ▼ $1.40	$17.28M	0.78	363,740 shs	751,230 shs
LPCN Lipocine	$2.05 -2.8%	$2.26	$1.81 ▼ $12.37	$16.89M	0.46	218,106 shs	30,289 shs
REVB Revelation Biosciences	$1.15 +9.6%	$1.05	$0.88 ▼ $11.72	$4.58M	-0.15	292,181 shs	61,476 shs
TVRD Tvardi Therapeutics	$1.86 -2.1%	$2.49	$1.50 ▼ $43.65	$17.45M	0.39	973,201 shs	213,557 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	0.00%	+2.36%	+19.27%	+63.62%	+39.78%
LPCN Lipocine	0.00%	-0.94%	-5.38%	-4.52%	-30.36%
REVB Revelation Biosciences	0.00%	-7.02%	-10.17%	+1.92%	-89.73%
TVRD Tvardi Therapeutics	0.00%	+1.60%	-40.63%	-52.50%	-92.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$1.35 +3.8%	$1.08	$0.55 ▼ $1.40	$17.28M	0.78	363,740 shs	751,230 shs
LPCN Lipocine	$2.05 -2.8%	$2.26	$1.81 ▼ $12.37	$16.89M	0.46	218,106 shs	30,289 shs
REVB Revelation Biosciences	$1.15 +9.6%	$1.05	$0.88 ▼ $11.72	$4.58M	-0.15	292,181 shs	61,476 shs
TVRD Tvardi Therapeutics	$1.86 -2.1%	$2.49	$1.50 ▼ $43.65	$17.45M	0.39	973,201 shs	213,557 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	0.00%	+2.36%	+19.27%	+63.62%	+39.78%
LPCN Lipocine	0.00%	-0.94%	-5.38%	-4.52%	-30.36%
REVB Revelation Biosciences	0.00%	-7.02%	-10.17%	+1.92%	-89.73%
TVRD Tvardi Therapeutics	0.00%	+1.60%	-40.63%	-52.50%	-92.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRI Biofrontera	2.00	Hold	N/A	N/A
LPCN Lipocine	1.50	Reduce	$15.00	621.50% Upside
REVB Revelation Biosciences	1.00	Sell	N/A	N/A
TVRD Tvardi Therapeutics	2.78	Moderate Buy	$18.00	856.94% Upside

Current Analyst Ratings Breakdown

Latest REVB, LPCN, TVRD, and BFRI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/30/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
7/28/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/15/2026	BFRI Biofrontera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/9/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/8/2026	TVRD Tvardi Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	TVRD Tvardi Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform	$10.00
7/8/2026	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$13.00
7/8/2026	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$10.00
7/7/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRI Biofrontera	$41.71M	0.41	N/A	N/A	$0.90 per share	1.49
LPCN Lipocine	$1.98M	8.65	N/A	N/A	$2.61 per share	0.80
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	$1.28 per share	N/A
TVRD Tvardi Therapeutics	$7.14M	2.47	N/A	N/A	$2.23 per share	0.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRI Biofrontera	-$10.54M	-$0.45	N/A	N/A	N/A	-13.78%	-145.81%	-31.30%	N/A
LPCN Lipocine	-$9.63M	-$1.79	N/A	N/A	N/A	-755.39%	-64.75%	-57.62%	11/5/2026 (Estimated)
REVB Revelation Biosciences	-$8.91M	-$12.31	N/A	N/A	N/A	N/A	-100.19%	-82.72%	11/5/2026 (Estimated)
TVRD Tvardi Therapeutics	-$18.21M	-$3.10	N/A	N/A	N/A	N/A	-123.49%	-80.68%	N/A

Latest REVB, LPCN, TVRD, and BFRI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	TVRD Tvardi Therapeutics	-$0.65	-$0.69	-$0.04	-$0.69	N/A	N/A
8/13/2026	Q2 2026	BFRI Biofrontera	-$0.1050	-$0.05	+$0.0550	-$0.05	$9.50 million	$12.00 million
8/7/2026	Q2 2026	REVB Revelation Biosciences	-$0.8750	-$0.87	+$0.0050	-$0.87	N/A	N/A
8/4/2026	Q2 2026	LPCN Lipocine	-$0.40	-$0.32	+$0.08	-$0.32	$0.21 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRI Biofrontera	0.78	1.18	1.08
LPCN Lipocine	N/A	11.48	11.48
REVB Revelation Biosciences	N/A	6.22	6.22
TVRD Tvardi Therapeutics	N/A	2.25	2.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRI Biofrontera	10.08%
LPCN Lipocine	9.11%
REVB Revelation Biosciences	12.80%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
BFRI Biofrontera	8.10%
LPCN Lipocine	4.69%
REVB Revelation Biosciences	4.80%
TVRD Tvardi Therapeutics	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRI Biofrontera	70	12.80 million	11.77 million	No Data
LPCN Lipocine	10	8.24 million	7.86 million	No Data
REVB Revelation Biosciences	10	3.98 million	3.79 million	Not Optionable
TVRD Tvardi Therapeutics	80	9.38 million	8.69 million	N/A

REVB, LPCN, TVRD, and BFRI Headlines

Recent News About These Companies

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

August 14 at 7:00 AM | globenewswire.com

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

August 12, 2026 | globenewswire.com

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical Trial

July 30, 2026 | quiverquant.comQ

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

July 30, 2026 | globenewswire.com

Tvardi Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:TVRD

July 23, 2026 | benzinga.com

Tvardi Therapeutics Inc TVRD

July 14, 2026 | morningstar.comM

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

July 10, 2026 | theglobeandmail.com

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

July 9, 2026 | zacks.com

Tvardi Therapeutics Reports Phase 1 Data for TTI-109

July 8, 2026 | theglobeandmail.com

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

July 7, 2026 | investorideas.comI

Tvardi Therapeutics Inc.

July 7, 2026 | cnn.com

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

July 7, 2026 | finance.yahoo.com

Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

July 7, 2026 | globenewswire.com

TVRD Share News Today

June 29, 2026 | uk.investing.com

Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting

June 27, 2026 | theglobeandmail.com

Tvardi Therapeutics, Inc. Common Stock

June 27, 2026 | fxempire.comF

H.C. Wainwright Initiates a Buy Rating on Tvardi Therapeutics (TVRD)

June 25, 2026 | theglobeandmail.com

Tvardi Therapeutics Shareholders Approve Directors and Governance Measures

June 11, 2026 | tipranks.com

Tvardi Therapeutics to Participate in Upcoming Investor Events

May 21, 2026 | globenewswire.com

Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)

May 13, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB, LPCN, TVRD, and BFRI Company Descriptions

Biofrontera NASDAQ:BFRI

$1.35 +0.05 (+3.85%)

As of 04:00 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Lipocine NASDAQ:LPCN

$2.05 -0.06 (-2.84%)

As of 04:00 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Revelation Biosciences NASDAQ:REVB

$1.15 +0.10 (+9.63%)

As of 04:00 PM Eastern

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Tvardi Therapeutics NASDAQ:TVRD

$1.86 -0.04 (-2.11%)

As of 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REVB, LPCN, TVRD, and BFRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REVB, LPCN, TVRD, and BFRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REVB, LPCN, TVRD, and BFRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB, LPCN, TVRD, and BFRI Company Descriptions

Biofrontera NASDAQ:BFRI

Lipocine NASDAQ:LPCN

Revelation Biosciences NASDAQ:REVB

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REVB, LPCN, TVRD, and BFRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REVB, LPCN, TVRD, and BFRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REVB, LPCN, TVRD, and BFRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB, LPCN, TVRD, and BFRI Company Descriptions

Biofrontera NASDAQ:BFRI

Lipocine NASDAQ:LPCN

Revelation Biosciences NASDAQ:REVB

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools